Last updated on January 2019

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis


Brief description of study

The purpose of this study is to evaluate the efficacy of pimavanserin by comparing pimavanserin with placebo in preventing a relapse of psychotic symptoms in subjects with dementia-related psychosis and who were stabilized after 12 weeks of open label pimavanserin treatment.

Clinical Study Identifier: NCT03325556

Contact Investigators or Research Sites near you

Start Over

Scott Stubbe

Memory Enhancement Center of America, Inc.
Eatontown, NJ United States
1.0miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.